Haleos Labs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Haleos Labs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 94% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 94% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹205Over the last 3 years, every ₹100 of reported profit came with ₹205 of operating cash.
Higher than 88% of Healthcare companies in India.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 65% of Healthcare companies in India.
Cash Locked Ratio
₹19For every ₹100 of sales, ₹19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹18 tied up three years earlier.
Less money tied up than 61% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+1% / +15%In 3 years sales changed by +1% while total assets changed by +15%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.6×Debt due within a year is covered 0.6 times by its yearly operating cash.
Lower than 67% of Healthcare companies in India.
Cash Cushion Ratio
−22%Debt, after subtracting cash, equals 22% of its market value (net debt).
Lower than 93% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 94% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 94% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Haleos Labs Limited owes ₹0.49 for every ₹1 it owns. Net profit fell 14% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
30.8Investors pay ₹30.8 for every ₹1 of Haleos Labs Limited's yearly profit, lower than 63% of Healthcare companies in India.
P/B ratio
2.28The share price is 2.28 times Haleos Labs Limited's book value per share, lower than 81% of Healthcare companies in India.
Market cap
₹487 CrThe total market value of all of Haleos Labs Limited's shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹214 CrWhat Haleos Labs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹706.34Net worth divided by the number of shares. The share price of ₹1,611 is 2.3 times this, which is the P/B above.
Return on equity (ROE)
7.4%Haleos Labs Limited earned 7.4% on its shareholders' money over the last year, lower than 77% of Healthcare companies in India.
Owes vs Owns
0.49×Haleos Labs Limited owes ₹0.49 for every ₹1 it owns (low), higher than 83% of Healthcare companies in India.
Dividend yield
0.10%Haleos Labs Limited pays 0.10% of its share price as dividends a year, lower than 88% of dividend-paying Healthcare companies in India.
Revenue growth
-6%Revenue fell 6% in the year to Mar 2026, and grew 0% a year on average over 3 years.
Profit growth
-14%Net profit fell 14% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit margin
5.5%Haleos Labs Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
2.2×Cash from Haleos Labs Limited's business was 2.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.9×Haleos Labs Limited's operating profit covered its interest costs 4.9 times in the year to Mar 2026.
Cash vs debt
Net debtHaleos Labs Limited had ₹109 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Haleos Labs Limited's P/E ratio?
Investors pay ₹30.8 for every ₹1 of Haleos Labs Limited's yearly profit, lower than 63% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Haleos Labs Limited: ₹487 Cr ÷ ₹214 Cr (31 Mar 2026) = 2.3.
What is Haleos Labs Limited's return on equity?
Haleos Labs Limited earned 7.4% on its shareholders' money over the last year, lower than 77% of Healthcare companies in India.
How much does Haleos Labs Limited owe compared with what it owns?
Haleos Labs Limited owes ₹0.49 for every ₹1 it owns (low), higher than 83% of Healthcare companies in India.
Does Haleos Labs Limited pay a dividend?
Yes. Haleos Labs Limited pays 0.10% of its share price as dividends a year, lower than 88% of dividend-paying Healthcare companies in India.
Is Haleos Labs Limited's revenue growing?
Revenue fell 6% in the year to Mar 2026, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.